Skip To Main Content
S. Steen on Muck Rack

S. Steen

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to S. Steen’s profile

Articles by S. Steen

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease | Nature Aging

|
By M. Werner, A. McGarry, C. R. Meyer, E. Mancino, C. Klint, J. Gabriella Pellecchia, K. Kieburtz, T. Levine, B. Bellaire, C. Gibbons, R. Parrish Freeman, A. Ellenbogen, K. Klos, M. Ospina, R. Hauser, K. Shannon, H. Asaad, A. Park, P. McAllister, S. H. Isaacson, M. LeDoux, R. Dhall, D. Shpiner, P. Charles, P. K. Agarwal, E. Peckham, P. Mazzeo, M. M. Davis, R. Pahwa, M. Brodsky, M. Lew, L. Purino, S. Mantri, S. Parashos, W. Justiz, M. Chachar, B. Robottom, E. Budman, K. Blindauer, S. Bellows, J. Goudreau, S. Steen, C. W. Olanow
| Nature Verified
Abstract The nonreceptor Abelson (Abl) tyrosine kinases have been implicated as key drivers of initiation and progression in Parkinson’s disease (PD). Risvodetinib, a potent, brain-penetrant, selective inhibitor of the nonreceptor Abl kinases c-Abl1 and c-Abl2/Arg (collectively, c-Abl), was evaluated in a randomized, double-blind, placebo-controlled phase 2a trial (‘the 201 Trial’) using once-daily 50 mg, 100 mg, 200 mg or placebo in 137 participants with early, untreated PD.
Open in Who Shared Issue with article?
Show More